A Real-World Analysis of Relapse Rate and Efficacy of a Restricted Monthly Dose of Omalizumab in Recalcitrant Chronic Spontaneous Urticaria in India

Detalles Bibliográficos
Autores principales: Sardana, Kabir, Dixit, Niharika, Arora, Pooja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Concise Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678515/
https://www.ncbi.nlm.nih.gov/pubmed/33235861
http://dx.doi.org/10.4103/idoj.IDOJ_499_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678515/
https://www.ncbi.nlm.nih.gov/pubmed/33235861
http://dx.doi.org/10.4103/idoj.IDOJ_499_19

Ejemplares similares